Sulfhemoglobinemia in a 53-Year-Old With a History of Phenazopyridine Misuse.

adverse reaction dyshemoglobinemia phenazopyridine sulfhemoglobinemia toxicology

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
Jun 2023
Historique:
accepted: 24 06 2023
medline: 27 7 2023
pubmed: 27 7 2023
entrez: 27 7 2023
Statut: epublish

Résumé

Sulfhemoglobin is formed by the irreversible bonding of sulfur atoms to the heme molecule. Oxygen is then unable to bind the heme molecule, rendering the hemoglobin molecule unable to carry oxygen. The most common etiology of sulfhemoglobinemia is the use/misuse of sulfur-containing medications such as AZO. Unlike methemoglobin, sulfhemoglobin, due to its irreversible binding, has no antidote, and the treatment is ultimately supportive. We present a case of a 53-year-old female who presented to the emergency room endorsing dysuria and was noted to have abnormally low oxygen saturation (SpO2) despite having high arterial oxygen pressure (PaO2) on blood gas. History was significant for dysuria developed while traveling and the use of over-the-counter AZO four times daily for the past 10 days. She was diagnosed with a presumed dyshemoglobinemia and, upon return of send-out labs, was confirmed to have sulfhemoglobinemia attributed to phenazopyridine. This case highlights the importance of the recognition of potential dyshemoglobinemias and consideration of sulfhemoglobinemia as a potential causative etiology, especially in patients taking sulfur-containing medications.

Identifiants

pubmed: 37496545
doi: 10.7759/cureus.40944
pmc: PMC10368485
doi:

Types de publication

Case Reports

Langues

eng

Pagination

e40944

Informations de copyright

Copyright © 2023, Soderstrom et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Springerplus. 2015 Oct 19;4:626
pubmed: 26543761
Medicine (Baltimore). 2004 Sep;83(5):265-273
pubmed: 15342970
Pediatrics. 2015 Dec;136(6):e1641-5
pubmed: 26553186
Lancet. 2007 Jun 9;369(9577):1972
pubmed: 17560450
Clin Chem. 1997 Jun;43(6 Pt 1):1098-9
pubmed: 9191578
West J Emerg Med. 2009 Aug;10(3):197-201
pubmed: 19718385
Anesthesiology. 2000 Sep;93(3):883-4
pubmed: 10969324
Respir Med Case Rep. 2017 Mar 14;21:21-24
pubmed: 28348950
N Engl J Med. 1948 Sep 23;239(13):470-8
pubmed: 18883450
J Biomed Opt. 2012 Sep;17(9):97005
pubmed: 22975680
Am J Gastroenterol. 1995 Jun;90(6):1010-1
pubmed: 7771397
Biomed Opt Express. 2018 Jun 25;9(7):3284-3305
pubmed: 29984098
Ann Pharmacother. 2005 Jun;39(6):1128-30
pubmed: 15886294
Int J Lab Hematol. 2021 Aug;43(4):837-844
pubmed: 34092029

Auteurs

Matthew Soderstrom (M)

Department of Internal Medicine, Brooke Army Medical Center, San Antonio, USA.

Daniel V Foster (DV)

Department of Pulmonary and Critical Care Medicine, Brooke Army Medical Center, San Antonio, USA.

Zachariah S Hamidi (ZS)

Department of Internal Medicine, Brooke Army Medical Center, San Antonio, USA.

Jess T Anderson (JT)

Department of Pulmonary and Critical Care Medicine, Brooke Army Medical Center, San Antonio, USA.

Classifications MeSH